Search

Search Constraints

You searched for: Subject 610.5

Search Results

651. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Issue 10191 (29th June 2019)

656. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Issue 10270 (16th January 2021)

657. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial. Issue 10127 (31st March 2018)